Suscribirse

Fasting plasma glucose variability in midlife and risk of Parkinson's disease: A nationwide population-based study - 20/05/21

Doi : 10.1016/j.diabet.2020.08.006 
H.S. Chung a, 1, J.S. Lee b, 1, J.A. Kim c, E. Roh c, Y.-B. Lee c, S.-h. Hong c, J.H. Yu c, N.H. Kim c, H.J. Yoo c, J.A. Seo c, S.G. Kim c, N.H. Kim c, S.H. Baik c, K.M. Choi c,
a Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangnam Sacred Heart Hospital, College of Medicine, Hallym University of Korea, Seoul, South Korea 
b Clinical Research Centre, Asan Medical Centre, College of Medicine, Ulsan University of Korea, Seoul, South Korea 
c Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Korea University, Seoul, South Korea 

Corresponding author at: Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Guro Hospital, 80 Guro-Dong, Guro-Gu, Seoul 08308, South Korea.Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Guro Hospital80 Guro-DongGuro-GuSeoul08308South Korea

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Aim

Despite the recognized association between type 2 diabetes (T2D) and Parkinson's disease (PD), the implications of glycaemic variability for patients with PD are as yet unknown. For this reason, our study assessed the future risk of incident PD according to visit-to-visit fasting plasma glucose (FPG) variability, as calculated by standard deviation (FPG-SD), coefficient variance (FPG-CV) and variability independent of the mean (FPG-VIM).

Methods

Using the Korean National Health Insurance Service Health Screening Cohort, 131,625 Korean adults without diabetes were followed. They were divided into a midlife group (age<65 years) and an elderly group (age65 years) throughout a median follow-up of 8.4 years.

Results

Adjusted hazard ratios (HRs) were calculated using multivariable Cox proportional-hazards analysis. In the midlife group, HRs for incident PD in the highest quartile of FPG variability (as measured by SD, CV and VIM) were 1.37 [95% confidence interval (CI): 1.09–1.73], 1.33 (95% CI: 1.06–1.68) and 1.35 (95% CI: 1.07–1.70), respectively, vs the lowest variability quartile group. However, while incident PD did not differ according to FPG variability in the elderly group, Kaplan–Meier curves of PD probability in the midlife group showed a progressively increasing risk of PD the higher the FPG variability. According to a multivariable adjusted model, every 1-SD unit increment in glycaemic variability was associated with a 9% higher risk of incident PD in the midlife group.

Conclusion

Increased long-term glycaemic variability may be a precipitating risk factor for developing PD in the midlife population without diabetes.

El texto completo de este artículo está disponible en PDF.

Abbreviations : AD, BMI, CI, CKD, CV, DPP-4, FPG, HbA1c, HR, ICD-10, NHIS-HEALS, PD, SD, VIM

Keywords : Fasting plasma glucose, Glycaemic variability, Midlife, Parkinson's disease, Visit-to-visit


Esquema


© 2020  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 47 - N° 3

Artículo 101195- mai 2021 Regresar al número
Artículo precedente Artículo precedente
  • Prognosis associated with initial care of increased fasting glucose in early pregnancy: A retrospective study
  • E. Cosson, E. Vicaut, N. Berkane, T.L. Cianganu, C. Baudry, J.-J. Portal, J. Boujenah, P. Valensi, L. Carbillon
| Artículo siguiente Artículo siguiente
  • Practical implementation of automated closed-loop insulin delivery: A French position statement
  • N. Tubiana-Rufi, P. Schaepelynck, S. Franc, L. Chaillous, M. Joubert, E. Renard, Y. Reznik, C. Abettan, E. Bismuth, J. Beltrand, E. Bonnemaison, S. Borot, G. Charpentier, B. Delemer, A. Desserprix, D. Durain, A. Farret, N. Filhol, B. Guerci, I. Guilhem, C. Guillot, N. Jeandidier, S. Lablanche, R. Leroy, V. Melki, M. Munch, A. Penfornis, S. Picard, J. Place, J.P. Riveline, P. Serusclat, A. Sola-Gazagnes, C. Thivolet, H. Hanaire, P.Y. Benhamou, on behalf of the SFD SFD Paramedical SFE SFEDP AJD FFD FENAREDIAM and CNP-EDN

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.